Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jun 22, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, June 24, 2015.
Jun 18, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23 rd  at 12:00 p.m.
Jun 17, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately. Mr.
Jun 03, 2015
Collaboration involves two proprietary Merck targets LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that Merck, known as MSD outside the United States and Canada, through a
Jun 01, 2015
Most significant improvements seen in patients with less elevated PD-L1 expression in peripheral blood Improvement in overall survival seen independent of MGMT methylation status LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing innovative treatments
May 28, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the Jefferies 2015 Healthcare Conference on Thursday, June 4 th  at 1:00 p.m. Eastern Time.
May 21, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and immune adjuvants, today announced that it intends to offer and sell, subject to market conditions, shares
May 21, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per
May 08, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming analyst and institutional investor meeting to be held on Thursday, May 14, 2015, from 4:30 to 6:30 PM Eastern Time in New York City.
Apr 23, 2015
Corporate Update Conference Call at 11 am ET Today Agenus to Host R&D Day in New York, NY on May 14 LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well
Apr 08, 2015
SECANT® yeast display technology to provide speed and cost advantages Combination with Agenus’ mammalian Retrocyte DisplayTM technology to result in a uniquely powerful antibody platform LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative
Feb 26, 2015
Agenus to host conference call at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing novel therapeutic approaches based on checkpoint modulators (CPMs), heat shock protein-based vaccines, and immune adjuvants, today announced its
Feb 25, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein-based vaccines, as well as immune adjuvants, today announced that the Company will present at the Cowen and Company 35 th
Feb 03, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and immune adjuvants, today announced that the Company will present at the 17 th  Annual BIO CEO &
Oct 31, 2014
Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a development pipeline of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced its